 <h1>Afatinib Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2>In Summary</h2><p><b>Commonly reported side effects of afatinib include:</b> diarrhea, abnormal hepatic function tests, acneiform eruption, skin rash, and erythema of skin. <b>Other side effects include:</b> palmar-plantar erythrodysesthesia, and renal insufficiency.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to afatinib: oral tablet</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, afatinib may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking afatinib:</p><p>
<i>More common</i>
</p><ul>
<li>Bloody or cloudy urine</li>
<li>burning, dry, or itching eyes</li>
<li>diarrhea</li>
<li>difficult, burning, or painful urination</li>
<li>discharge or excessive tearing</li>
<li>fever</li>
<li>frequent urge to urinate</li>
<li>redness, pain, or swelling of the eye, eyelid, or inner lining of the eyelid</li>
<li>redness, swelling, or pain of the skin</li>
<li>scaling of the skin on the hands and feet</li>
<li>tingling of the hands and feet</li>
<li>ulceration of the skin</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Cough</li>
<li>difficult breathing</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Bloody, black, or tarry stools</li>
<li>heartburn</li>
<li>indigestion</li>
<li>nausea</li>
<li>severe abdominal pain, cramping, or burning</li>
<li>vomiting of material that looks like coffee grounds, severe and continuing</li>
</ul><p>
<i>Get emergency help immediately if any of the following symptoms of overdose occur while taking afatinib:</i>
</p><p>
<i>Symptoms of overdose</i>
</p><ul>
<li>Dizziness</li>
<li>headache</li>
<li>lack or loss of strength</li>
<li>stomach pain</li>
<li>vomiting</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of afatinib may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Blemishes on the skin</li>
<li>canker sores</li>
<li>chapped, red, or swollen lips</li>
<li>decreased appetite</li>
<li>decreased weight</li>
<li>dry skin</li>
<li>itching skin or rash</li>
<li>loosening of the fingernails</li>
<li>nosebleeds</li>
<li>pimples</li>
<li>redness or soreness around the fingernails</li>
<li>runny nose</li>
<li>scaling, redness, burning, pain, or other signs of inflammation of the lips</li>
<li>sores, ulcers, or white spots on the lips or tongue or inside the mouth</li>
</ul><p>
<!-- end oral tablet --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to afatinib: oral tablet</i></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea (96%), stomatitis (71%), cheilitis (12%), nausea, vomiting</p>
<p><b>Common</b> (1% to 10%): Dyspepsia</p>
<p><b>Uncommon</b> (0.1% to 1%): Pancreatitis<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Acneiform rash/dermatitis (90%), paronychia (58%), dry skin (31%), pruritus (21%), alopecia (13%)</p>
<p><b>Common</b> (1% to 10%): Palmar-plantar erythrodysesthesia syndrome, nail disorders</p>
<p><b>Uncommon</b> (0.1% to 1%): Bullous, blistering, and exfoliating lesions</p>
<p><b>Rare</b> (0.01% to 0.1%): Stevens-Johnson syndrome, toxic epidermal necrolysis (TEN)<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Very common</b> (10% or more): Cystitis (13%)<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Alanine aminotransferase increased (11%)</p>
<p><b>Common</b> (1% to 10%): Aspartate aminotransferase increased<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Decreased appetite (29%), weight decreased (17%)</p>
<p><b>Common</b> (1% to 10%): Dehydration, hypokalemia<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Very common</b> (10% or more): Conjunctivitis (11%)</p>
<p><b>Common</b> (1% to 10%): Dry eye</p>
<p><b>Uncommon</b> (0.1% to 1%): Keratitis (e.g., acute or worsening eye inflammation, lacrimation, light sensitivity, blurred vision, eye pain, and/or red eye)<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue (19%), pyrexia (12%)<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Epistaxis (17%), nasopharyngitis (14%), rhinorrhea (11%)</p>
<p><b>Uncommon</b> (0.1% to 1%): Interstitial lung disease (ILD) or ILD-like adverse reactions (e.g., lung infiltration, pneumonitis, acute respiratory distress syndrome, alveolitis allergic)<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Muscle spasm<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Very common</b> (10% or more): Insomnia (15%)<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (14%), dizziness (11%)</p>
<p><b>Common</b> (1% to 10%): Dysgeusia<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Common</b> (1% to 10%): Renal impairment/renal failure<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Gilotrif (afatinib)." Boehringer Ingelheim, Ridgefield, CT. </p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_3">3. Cerner Multum,  Inc. "Australian Product Information." O 0</p></div>
<div class="more-resources" id="moreResources">
<h2>More about afatinib</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Espa√±ol</li>
<li>3 Reviews</li>
<li>Drug class: multikinase inhibitors</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Afatinib &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Gilotrif</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Non-Small Cell Lung Cancer</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to afatinib: oral tablet</i></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea (96%), stomatitis (71%), cheilitis (12%), nausea, vomiting</p><p><b>Common</b> (1% to 10%): Dyspepsia</p><p><b>Uncommon</b> (0.1% to 1%): Pancreatitis<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Acneiform rash/dermatitis (90%), paronychia (58%), dry skin (31%), pruritus (21%), alopecia (13%)</p><p><b>Common</b> (1% to 10%): Palmar-plantar erythrodysesthesia syndrome, nail disorders</p><p><b>Uncommon</b> (0.1% to 1%): Bullous, blistering, and exfoliating lesions</p><p><b>Rare</b> (0.01% to 0.1%): Stevens-Johnson syndrome, toxic epidermal necrolysis (TEN)<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Very common</b> (10% or more): Cystitis (13%)<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Alanine aminotransferase increased (11%)</p><p><b>Common</b> (1% to 10%): Aspartate aminotransferase increased<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Decreased appetite (29%), weight decreased (17%)</p><p><b>Common</b> (1% to 10%): Dehydration, hypokalemia<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Very common</b> (10% or more): Conjunctivitis (11%)</p><p><b>Common</b> (1% to 10%): Dry eye</p><p><b>Uncommon</b> (0.1% to 1%): Keratitis (e.g., acute or worsening eye inflammation, lacrimation, light sensitivity, blurred vision, eye pain, and/or red eye)<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue (19%), pyrexia (12%)<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Epistaxis (17%), nasopharyngitis (14%), rhinorrhea (11%)</p><p><b>Uncommon</b> (0.1% to 1%): Interstitial lung disease (ILD) or ILD-like adverse reactions (e.g., lung infiltration, pneumonitis, acute respiratory distress syndrome, alveolitis allergic)<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Muscle spasm<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Very common</b> (10% or more): Insomnia (15%)<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (14%), dizziness (11%)</p><p><b>Common</b> (1% to 10%): Dysgeusia<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Common</b> (1% to 10%): Renal impairment/renal failure<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Gilotrif (afatinib)." Boehringer Ingelheim, Ridgefield, CT. </p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_3">3. Cerner Multum,  Inc. "Australian Product Information." O 0</p><h2>More about afatinib</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Espa√±ol</li>
<li>3 Reviews</li>
<li>Drug class: multikinase inhibitors</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Afatinib &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Non-Small Cell Lung Cancer</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>